Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2
Information source: Danish Headache Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Headache; Migraine
Intervention: PGE2 (Drug)
Phase: N/A
Status: Completed
Sponsored by: Danish Headache Center Official(s) and/or principal investigator(s):
Troels Wienecke, MD, Principal Investigator, Affiliation: Danish Headache Center
Summary
Before, during and after intravenous administration of PGE2 we score/measure headache, rCBF,
blood flow in the middle cerebral artery and diameter of superficial temporal artery and
correlate that to known pathophysiology of headache to see if PGE2 is involved in headache
pathophysiology.
Clinical Details
Official title: Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of PGE2
Study design: Randomized, Double-Blind, Placebo Control, Crossover Assignment
Primary outcome: Headache
Secondary outcome: rCBF, blood flow, diameter of STA/RA, HR, BP
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy volunteers
Exclusion Criteria:
- Primary Headache, headache on the day of the investigation, hypertension, hypotension,
pregnant/nursing, daily intake of medication (except oral contraceptives),
Cardiovascular or CNS disease, drug/alcohol abuse, psychiatric disease
Locations and Contacts
Danish Headache Center, Glostrup DK-2600, Denmark
Additional Information
Starting date: August 2006
Last updated: July 31, 2007
|
